Indeed, studies that evaluated CSF-1 receptor inhibition in combination with ICI treatment showed synergy of both agents and promising tumour regression, suggesting that CSF-1 receptor inhibitors can help to overcome tumour resistance to immunotherapy[117,118]. Here, CSF1R is linked to neoplasm.